RECRUITING

Mindfulness and Placebo for Pain (MAPP) Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study proposes a three-arm randomized-controlled trial (RCT) that evaluates the feasibility and acceptability of combining a mindfulness-based therapy (MBT) and open-label placebo (OLP) treatment for individuals with chronic pain. Individuals with chronic pain will be recruited to participate in an 8-week trial, with a subsequent 3-month post-treatment follow-up. Participants will be randomly assigned to one of the following three conditions: 1. Mindfulness-Based Stress Reduction (MBSR) 2. OLP treatment 3. combination of MBSR and OLP treatment

Official Title

Feasibility of Combining Mindfulness Intervention and Open-Label Placebo Treatment for Chronic Pain

Quick Facts

Study Start:2025-01-27
Study Completion:2027-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06720909

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. ≥18 years old;
  2. 2. ability to speak, write, and read in English;
  3. 3. physical pain present on at least half the days in the past 3 months; and
  4. 4. average past week pain severity rating ≥3 on a 0-10 Numerical Rating Scale.
  1. 1. acute pain due to recent injury or surgery;
  2. 2. self-reporting of chronic malignant pain (e.g., cancer, HIV);
  3. 3. self-reporting of Raynaud's disease (those who can be contraindicated for cold pressor testing);
  4. 4. severe psychopathology (e.g., a psychotic disorder) or significant cognitive deficits judged to interfere with study procedures;
  5. 5. currently pregnant or breastfeeding;
  6. 6. inability to discontinue use of vitamin B2 supplements or a multivitamin containing vitamin B2 throughout the study period (these interfere with riboflavin tracer-OLP treatment adherence-monitoring);
  7. 7. inability to commit to study period.

Contacts and Locations

Study Contact

Chung Jung Mun, PhD
CONTACT
602-496-0809
chungjung.mun@asu.edu
Ryan Eckert, MS
CONTACT
602-496-0665
ryan.eckert@asu.edu

Principal Investigator

Chung Jung Mun, PhD
PRINCIPAL_INVESTIGATOR
Arizona State University

Study Locations (Sites)

Arizona State University Downtown Phoenix Campus
Phoenix, Arizona, 85004
United States
Arizona State University
Phoenix, Arizona, 85004
United States

Collaborators and Investigators

Sponsor: Arizona State University

  • Chung Jung Mun, PhD, PRINCIPAL_INVESTIGATOR, Arizona State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-27
Study Completion Date2027-03

Study Record Updates

Study Start Date2025-01-27
Study Completion Date2027-03

Terms related to this study

Keywords Provided by Researchers

  • chronic pain
  • pain
  • mindfulness
  • placebo

Additional Relevant MeSH Terms

  • Chronic Pain